Drug intelligence / Profile preview

alendronate + hyaluronan + curcumin

Development stage: Preclinical
Modality: Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

This combination involves alendronate, hyaluronic acid, and curcumin, formulated into micelles for targeted therapy, particularly for osteosarcoma. Alendronate is a bisphosphonate used in bone diseases, hyaluronic acid is a natural polymer with various medical applications, and curcumin is a compound with potential antitumor effects. The micelles are designed to target bone and tumors, enhancing the delivery of curcumin, which has limited solubility and bioavailability.

Other names: Dual targeting curcumin loaded alendronate-hyaluronan-octadecanoic acid micelles

Targets

CD44 (CD44 antigen)

Beyond the preview

Go deeper on alendronate + hyaluronan + curcumin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alendronate + hyaluronan + curcumin.

Explore the full profile